Compare PLRX & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLRX | VINP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Brazil |
| Employees | 49 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 638.8M |
| IPO Year | 2020 | 2020 |
| Metric | PLRX | VINP |
|---|---|---|
| Price | $1.08 | $9.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 385.6K | 41.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.72% |
| EPS Growth | ★ 29.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.07 |
| Revenue Next Year | N/A | $12.74 |
| P/E Ratio | ★ N/A | $24.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $9.13 |
| 52 Week High | $1.95 | $13.61 |
| Indicator | PLRX | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 44.86 |
| Support Level | $1.02 | $9.31 |
| Resistance Level | $1.37 | $10.21 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 9.09 | 22.99 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.